BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30061258)

  • 21. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
    Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
    J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyloric gland adenoma in Lynch syndrome.
    Lee SE; Kang SY; Cho J; Lee B; Chang DK; Woo H; Kim JW; Park HY; Do IG; Kim YE; Kushima R; Lauwers GY; Park CK; Kim KM
    Am J Surg Pathol; 2014 Jun; 38(6):784-92. PubMed ID: 24518125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
    Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
    Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.
    Zighelboim I; Powell MA; Babb SA; Whelan AJ; Schmidt AP; Clendenning M; Senter L; Thibodeau SN; de la Chapelle A; Goodfellow PJ
    Fam Cancer; 2009; 8(4):501-4. PubMed ID: 19672700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of Turcot's syndrome type 1 with loss of immunoexpression of MSH6 in colon cancer and liver metastasis due to secondary somatic mutation in coding mononucleotide (C)8 tract: a case report.
    Akabane S; Hinoi T; Akagi K; Yamamoto H; Sada H; Shimizu Y; Shimizu W; Sudo T; Onoe T; Ishiyama K; Suzuki T; Tazawa H; Hadano N; Misumi T; Kojima M; Kubota H; Taniyama D; Kuraoka K; Tashiro H
    BMC Med Genet; 2020 Jul; 21(1):141. PubMed ID: 32611331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
    Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies.
    Vyas M; Firat C; Hechtman JF; Weiser MR; Yaeger R; Vanderbilt C; Benhamida JK; Keshinro A; Zhang L; Ntiamoah P; Gonzalez M; Andrade R; El Dika I; Markowitz AJ; Smith JJ; Garcia-Aguilar J; Vakiani E; Klimstra DS; Stadler ZK; Shia J
    Fam Cancer; 2021 Jul; 20(3):201-213. PubMed ID: 33033905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
    Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
    Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.
    Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
    Fam Cancer; 2006; 5(4):353-8. PubMed ID: 16817031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
    Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
    Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of microsatellite instability in endometroid carcinoma with deficient mismatch repair].
    Zhang YH; Wu HW; Wang J; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):470-475. PubMed ID: 33915653
    [No Abstract]   [Full Text] [Related]  

  • 33. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 34. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
    Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
    Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
    Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
    Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colorectal cancer in Lynch syndrome associated with PMS2 and MSH6 mutations.
    Yılmaz A; Mirili C; Bilici M; Tekin SB
    Int J Colorectal Dis; 2020 Feb; 35(2):351-353. PubMed ID: 31845022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.
    Rosty C; Walsh MD; Lindor NM; Thibodeau SN; Mundt E; Gallinger S; Aronson M; Pollett A; Baron JA; Pearson S; Clendenning M; Walters RJ; Nagler BN; Crawford WJ; Young JP; Winship I; Win AK; Hopper JL; Jenkins MA; Buchanan DD
    Fam Cancer; 2014 Dec; 13(4):573-82. PubMed ID: 25117503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.